Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CRHBP | P24387 | 2/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19010106 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| SCHEMBL12147343 | 0.91 | — | — | |
| SCHEMBL12147346 | 0.79 | PIK3CD (0.31) | — | |
| SCHEMBL9912001 | 0.74 | — | — | |
| SCHEMBL12147347 | 0.71 | — | — | |
| SCHEMBL10020968 | 0.69 | — | — | |
| SCHEMBL18881107 | 0.67 | — | — | |
| SCHEMBL12342362 | 0.67 | — | — | |
| SCHEMBL9672256 | 0.65 | — | — | |
| SCHEMBL19020657 | 0.65 | TTR (0.43) | SMN1; SMN2LMNACRHBPCRHR2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713322-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20170174697-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174697-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | SMN1; SMN2 4718/4885LMNA 4326/4885CRHBP 4446/4885 |
| US-11713322-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | ERBB2, ERBB4, ERBB3 | SMN1; SMN2 4747/4885LMNA 4309/4885CRHBP 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.